Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study

Ruan, Jia; Larson, Melissa C.; Chen, Zhengming; Bennani, N. Nora; Allen, Pamela B.; Jaye, David L.; Cohen, Jonathon B.; Chihara, Dai; Vega, Francisco; Inghirami, Giorgio; Mou, Eric; Casulo, Carla; Mehta-Shah, Neha; Martin, Peter; Maurer, Matthew J.; Kahl, Brad S.; Flowers, Christopher R.; Cerhan, James R.; Feldman, Andrew L.

doi:10.1182/blood-2022-164988

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort study highlighted continued poor outcomes of CHOP‐based induction chemotherapy from a large cohort ( N = 1132) of patients with PTCL treated in the contemporary era (2002 to 2020). Two‐year event‐free survival and 3‐year overall survival (OS) estimates were 46%–52% and 58%–61%, with anaplastic large cell lymphoma (ALCL) having superior survival and PTCL–not otherwise specified (NOS) and angioimmunoblastic lymphoma (AITL) having inferior outcomes 3 …”

Section: Introductionmentioning

confidence: 99%

“…Two-year event-free survival and 3-year overall survival (OS) estimates were 46%-52% and 58%-61%, with anaplastic large cell lymphoma (ALCL) having superior survival and PTCL-not otherwise specified (NOS) and angioimmunoblastic lymphoma (AITL) having inferior outcomes. 3 Several prognostic scores incorporating laboratory and clinical features have been proposed for PTCL, including the classical international prognostic index (IPI), age-adjusted IPI, the PINK-E score (incorporating age, stage, distant lymph node involvement, non-nasal type disease, and EBV-DNA) for extranodal NK/T-cell lymphoma, 4 and the T-cell score (incorporating age, stage, low albumin, and high absolute neutrophil count) derived from the international T-cell lymphoma project. 5 Increasingly, molecular profiling will improve risk stratification and help to tailor treatment for patients with PTCL.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

Ong,

Zain

2024

American J Hematol

View full text Add to dashboard Cite

IntroductionAggressive T‐cell lymphomas continue to have a poor prognosis. There are over 30 different subtypes of peripheral T‐cell lymphoma (PTCL), and we are now beginning to understand the differences between the various subtypes beyond histologic variations.Molecular Pathogenesis of Various Subtypes of PTCLGene expression profiling and other molecular techniques have enabled deeper understanding of differences in various subtypes as reflected in the latest 5th WHO classification of PTCL. It is becoming increasingly clear that therapeutic approaches that target specific cellular pathways are needed to improve the clinical outcomes of PTCL.Targeted TherapiesThere are many targeted agents currently in various stages of clinical trials for PTCL that take advantage of the differential expression of specific proteins or receptors in PTCL tumors. This includes the CD30 directed antibody drug conjugate brentuximab vedotin. Other notable targets are phosphatidylinositol 3‐kinase inhibitors, histone deacetylase inhibitors, CD25, and chemokine receptor 4. Anaplastic lymphoma kinase (ALK) inhibitors are promising for ALK expressing tumors.ImmunotherapiesAllogeneic stem cell transplant continues to be the curative therapy for most aggressive subtypes of PTCL. The use of checkpoint inhibitors in the treatment of PTCL is still controversial, with best results seen in cases of extranodal natural killer cell/T‐cell lymphoma. Bispecific antibody‐based treatments and chimeric antigen receptor cell‐based therapies are in clinical trials.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

Ong,

Zain

2024

American J Hematol

View full text Add to dashboard Cite

show abstract

SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas

Burton,

Foley,

Mehta-Shah

2024

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Peripheral T-cell lymphoma: are all patients high risk?

Shea,

Mehta-Shah

2024

Blood

View full text Add to dashboard Cite

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of mature T-cell neoplasms that represent approximately 10% of all non-Hodgkin Lymphoma (NHL). Outcomes for the majority of patients with PTCL are poor and treatment approaches have been relatively uniform using CHOP based therapy. For example, large registry studies consistently demonstrate 5-year overall survival (OS) of approximately 30-40%. However, as our understanding of the biology underpinning the heterogeneity of PTCL improves, and as treatments specifically for PTCL are developed, risk stratification has become a more relevant question. Tools including positron emission tomography-computed tomography (PET-CT) and minimal residual disease (MRD) monitoring offer the potential for dynamic risk stratification. In this review, we will first summarize registry data describing outcomes in the most common subtypes of PTCL - PTCL not otherwise specified (PTCL-NOS), nodal T-follicular helper cell lymphoma including angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL). We will describe current clinically based prognostic indices validated in PTCL and then highlight emerging tools for prognostication including novel molecular biomarkers, imaging-based metrics, and MRD dynamics.

show abstract

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study

Cited by 3 publications

References 0 publications

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas

Peripheral T-cell lymphoma: are all patients high risk?

Contact Info

Product

Resources

About